AF
FBIO icon

Amalgamated Financial’s Fortress Biotech FBIO Stock Holding History

Amalgamated Financial’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$16K Buy
+808
New +$22.1K ﹤0.01% 2798

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Amalgamated Financial's FBIO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Fortress Biotech (FBIO) in Q1 2022: 808 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #2798 among its holdings.

79 funds tracked by Wall St. Rank hold FBIO as of Q1 2022.

  • Amalgamated Financial held 808 shares of Fortress Biotech worth $16K as of Q1 2022.
  • Fortress Biotech was a new Amalgamated Financial position in Q1 2022.
  • Fortress Biotech made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2798 holding.
  • 79 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.